Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | QDPR | P09417 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17999702 | 0.84 | PIK3CD (0.39) | PIK3CDCYP1A2TDP1EPHX2CYP2D6 | |
| SCHEMBL12566544 | 0.84 | PIK3CD (0.39) | PIK3CDCYP1A2TDP1EPHX2CYP2D6 | |
| SCHEMBL29296169 | 0.81 | MEN1 (0.38) | EPHX2CYP2D6KCNH2HRH3MEN1 | |
| SCHEMBL2706023 | 0.76 | L3MBTL1 (0.30) | — | |
| SCHEMBL17973808 | 0.76 | L3MBTL1 (0.30) | — | |
| SCHEMBL29299287 | 0.75 | HSD11B1 (0.30) | — | |
| SCHEMBL680019 | 0.72 | PIK3CD (0.45) | PIK3CDCYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL20963235 | 0.71 | NCF1 (0.32) | — | |
| SCHEMBL37407 | 0.68 | — | — | |
| SCHEMBL860793 | 0.68 | CYP1A2 (0.77) | PIK3CDCYP1A2TDP1EPHX2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | PIK3CD 932/4885CYP1A2 4351/4885TDP1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.